Especially in germline testing of patients, who have a verified somatic pathogenic BRCA1/2 mutation in tumor tissue, or with no family history of HBOC but personal history suggestive of genetic predisposition, methods capable of identifying low-level mosaicism should be used. This evidence concerns the gene BRCA1 and neoplasm.